ESC: Amarin touts Vascepa’s ability to reduce repeat heart problems as it fights generic with ‘skinny label’ claimnews2021-08-23T15:17:59+00:00August 23rd, 2021|Fierce Pharma|
Pfizer, BioNTech score FDA’s first full COVID-19 vaccine nod, quickly triggering stricter mandatesnews2021-08-23T14:59:10+00:00August 23rd, 2021|Fierce Pharma|
After vandalism during unrest in South Africa, India-based Cipla reopens Durban manufacturing sitenews2021-08-23T13:59:21+00:00August 23rd, 2021|Fierce Pharma|
FDA puts Jubilant Generics plant through the wringer for cleaninless, quality flubsnews2021-08-23T13:34:17+00:00August 23rd, 2021|Fierce Pharma|
Coffee talk: Sun brings Ilumya patient stories to light with informal diner meetupsnews2021-08-23T13:15:47+00:00August 23rd, 2021|Fierce Pharma|
ESC 2021: Lexicon aims to make its heart failure case with sotagliflozin, a dual SGLT1 and SGLT2 inhibitornews2021-08-20T18:18:11+00:00August 20th, 2021|Fierce Pharma|
Covis granted FDA hearing in latest twist over controversial premature-birth med Makenanews2021-08-20T15:19:41+00:00August 20th, 2021|Fierce Pharma|
AstraZeneca’s Alexion buy takes first hit as Ultomiris fails in rare neurodegenerative diseasenews2021-08-20T14:56:13+00:00August 20th, 2021|Fierce Pharma|
FibroGen scores a lifeline as Astellas-partnered roxadustat snags EU approval, triggering $120M milestone paymentnews2021-08-20T13:29:02+00:00August 20th, 2021|Fierce Pharma|
Fierce Pharma Asia—China mRNA specialist’s $700M raise; Lilly-Innovent’s Tyvyt win; XtalPi’s AI financingnews2021-08-20T12:47:15+00:00August 20th, 2021|Fierce Pharma|
